| DC Field | Value | Language |
|---|
| dc.contributor.author | Azimova Mavlyuda Makhmudovna PhD, Associate Professor of department “Propaedeutics of Internal Diseases No. 2”, Tashkent State Medical University, Tashkent, Uzbekistan Irisbekov Behruz 3nd-year student, Faculty of General Medicine, Group 302B, Tashkent State Medical University, Tashkent, Uzbekistan | - |
| dc.date.accessioned | 2026-03-14T06:22:57Z | - |
| dc.date.available | 2026-03-14T06:22:57Z | - |
| dc.date.issued | 2026-02-28 | - |
| dc.identifier.uri | http://repo.tma.uz/xmlui/handle/1/3145 | - |
| dc.description.abstract | Systemic lupus erythematosus (SLE) is a chronic autoimmune connective tissue disorder with multiorgan involvement, characterized by impaired immunologic tolerance, B-cell hyperactivation, and activation of the interferon cascade. Contemporary diagnostic approaches include expanded immunologic profiling, molecular genetic studies, and the use of biomarkers of organ damage. SLE treatment is currently shifting from nonspecific immunosuppression toward personalized targeted therapy. The introduction of biologic agents and the treat-to- target strategy has substantially improved disease prognosis. | en_US |
| dc.language.iso | en | en_US |
| dc.subject | ystemic lupus erythematosus, autoimmune disease, antinuclear antibodies, EULAR/ACR 2019 criteria, lupus nephritis, interferon signature, targeted therapy, biologic agents, treat-to-target, immunologic biomarkers. | en_US |
| dc.title | Modern Methods of Diagnosis and Treatment of Systemic Lupus Erythematosus | en_US |
| dc.title.alternative | American Journal Of Biomedical Science & Pharmaceutical Innovation | en_US |
| dc.type | Article | en_US |
| Appears in Collections: |
|
